文献速递心力衰竭与心肌病血脂与心血管预防

恩格列净在常规临床实践中降低心衰住院风险:EMPRISE研究首次中期分析

Empagliflozin and the Risk of Heart Failure Hospitalization in Routine Clinical Care.
PubMed 文献 · Circulation · 2019-04-08

EMPRISE研究首次中期分析基于美国3个医保索赔数据库,纳入16,443对倾向评分匹配的2型糖尿病患者,比较恩格列净与西格列汀。平均随访5.3个月,恩格列净组心衰住院特异性风险降低50%(HR 0.50,95%CI 0.28-0.91),宽泛定义风险降低49%(HR 0.51,95%CI 0.39-0.68)。

要点

  • 常规诊疗中,恩格列净较西格列汀降低心衰住院风险约50%。
  • 获益在有无基线心血管疾病患者中一致,10mg和25mg剂量均一致。
  • SGLT2i与DPP-4i类效应比较结果一致,支持类效应。

核心结论

  • 在常规临床治疗的2型糖尿病患者中,起始恩格列净较西格列汀与心衰住院风险降低相关,无论有无心血管疾病史。

研究设计与样本

  • 基于美国2个商业和1个联邦(Medicare)索赔数据源的回顾性队列研究,采用1:1倾向评分匹配,纳入2014年8月至2016年9月起始恩格列净或西格列汀的≥18岁2型糖尿病患者,共16,443对匹配患者。

主要发现

  • 平均随访5.3个月,恩格列净较西格列汀降低心衰住院特异性风险50%(HR 0.50;95%CI 0.28-0.91)。
  • 恩格列净较西格列汀降低心衰住院宽泛定义风险49%(HR 0.51;95%CI 0.39-0.68)。
  • 结果在有无基线心血管疾病患者中一致,恩格列净10mg和25mg每日剂量均一致。
  • 恩格列净与DPP-4i类比较、SGLT2i与DPP-4i类比较均产生一致结果。

临床怎么用

  • 对于2型糖尿病患者,恩格列净可考虑用于降低心衰住院风险,尤其适用于有心血管疾病或心衰风险者。
  • 常规临床实践中恩格列净的心衰住院获益与EMPA-REG OUTCOME试验结果方向一致。

局限性

  • 首次中期分析,随访时间较短(平均5.3个月)。
  • 基于索赔数据,心衰住院定义依赖诊断编码,可能存在错分。
  • 观察性设计虽经倾向评分匹配,仍可能存在残余混杂。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The EMPA-REG OUTCOME trial (Empagliflozin Cardiovascular Outcome Event Trial in Type 2 diabetes Mellitus Patients) showed that empagliflozin, a sodium-glucose cotransporter-2 inhibitor, reduces the risk of hospitalization for heart failure (HHF) by 35%, on top of standard of care in patients with type 2 diabetes mellitus (T2D) and established cardiovascular disease. The EMPRISE (Empagliflozin Comparative Effectiveness and Safety) study aims to assess empagliflozin's effectiveness, safety, and healthcare utilization in routine care from August 2014 through September 2019. In this first interim analysis, we investigated the risk of HHF among T2D patients initiating empagliflozin versus sitagliptin, a dipeptidyl peptidase-4 inhibitor. METHODS: Within 2 commercial and 1 federal (Medicare) claims data sources in the United States, we identified a 1:1 propensity score-matched cohort of T2D patients ≥18 years old initiating empagliflozin or sitagliptin from August 2014 through September 2016. The HHF outcome was defined as a HF discharge diagnosis in the primary position (HHF-specific); a broader definition was based on a HF discharge diagnosis in any position (HHF-broad). Hazard ratios (HRs) and 95% CIs were estimated controlling for over 140 baseline characteristics in each data source and pooled by fixed-effects meta-analysis. RESULTS: After propensity-score matching, we identified 16,443 patient pairs who initiated empagliflozin or sitagliptin. Average age was approximately 59 years, almost 54% of the participants were males, and approximately 25% had records of existing cardiovascular disease. Compared with sitagliptin, the initiation of empagliflozin decreased the risk of HHF-specific by 50% (HR, 0.50; 95% CI, 0.28-0.91), and the risk of HHF-broad by 49% (HR, 0.51;95% CI, 0.39-0.68), over a mean follow-up of 5.3 months. The results were consistent in patients with and without baseline cardiovascular disease, and for empagliflozin at both the 10- and 25-mg daily doses; analyses comparing empagliflozin versus the dipeptidyl peptidase-4 inhibitor class, and comparing sodium-glucose cotransporter-2 inhibitor versus dipeptidyl peptidase-4 inhibitor classes also produced consistent findings. CONCLUSIONS: The first interim analysis from EMPRISE showed that compared with sitagliptin, the initiation of empagliflozin was associated with a decreased risk of HHF among patients with T2D as treated in routine care, with and without a history of cardiovascular disease. CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov . Unique identifier: NCT03363464.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Patorno E, Pawar A, Franklin JM, et al. Empagliflozin and the Risk of Heart Failure Hospitalization in Routine Clinical Care. Circulation. 2019. PMID: 30955357. doi:10.1161/CIRCULATIONAHA.118.039177

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。